The Global Liquid Biopsy market is expected to double during the forecast period with a CAGR of 24.3%
Hyderabad, India -- (SBWIRE) -- 01/30/2018 -- The report on "Liquid Biopsy Market by Cancer Type (Lung Cancer, Pancreatic Cancer, Leukemia and Other Visceral Cancers) by Sample Type (Blood, Urine, Plasma, Saliva and Cerebrospinal) by Diagnostic Approach (Circulating Tumour cells (CTC), Circulating Tumour DNA (ctDNA), RNA in exosomes and Extra-Cellular Vesicles), By End Users (Reference Laboratories, Hospital/Physician Laboratories, Academic and Research Centers, and Other End Users) and by Region - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)", is published by Market Data Forecast. The Global Liquid Biopsy Market was priced USD 590.2 million in 2016 and calculable to be growing at a CAGR of 24.3 %, to achieve USD 1.75 billion by 2021, in the forecast period from 2016 to 2021. The liquid biopsy technology consists of diagnostic and treatment procedures for medicine and it's believed to rework the clinical practice. A Liquid biopsy is used for diagnostic purposes, such as treatment monitoring in a blood test, expression profiling, and tumour diagnosis and response estimation. A liquid biopsy might capture the whole heterogeneity of the illness. This technique is advantageous for monitoring of a tumour genomic which is done by taking serial samples.
Browse through 178 Pages and in-depth TOC on "Liquid Biopsy Market "
The Global liquid biopsy is principally driven by factors like growing variety of products to support the development of the market, increasing the preference by oncologists for liquid biopsy, tolerability, and increasing adoption of personalised drugs, patient convenience. The Tissue biopsies are applicable not only for non-small cell lung cancers and these liquid biopsy procedures are used for replacing the tissue identification procedures in such situations is driving the expansion of this market. However, Liquid biopsy analysis Market requires a large amount of money and frequent clinical trials that are impeding the market growth.
Customized Report: https://www.marketdataforecast.com/market-reports/global-liquid-biopsy-market-950/customize-report
The fragmentation of liquid biopsy market is done on the basis of cancer type, end-users, diagnostic approach and sample type. On the idea of end users, the liquid biopsy market is classified as research centers, reference laboratories, academic, hospital/physician laboratories, and other end users. On the source of cancer type, the market is segregated into Leukaemia, Lung Cancer, Other Visceral Cancers, and Pancreatic Cancer. Based on sample type, the liquid biopsy market is divided into saliva, blood, Cerebrospinal fluid, plasma, and urine. On the origin of Diagnostic approach, the market is segregated into Extra-Cellular Vesicles, Circulating Tumour DNA (ctDNA), and RNA in exosomes, and Circulating Tumour cells (CTC). CTCs (Circulating neoplasm cells). Cancer Institute is the largest end user phase in terms of revenues and is predicted to make substantial opportunity in world liquid biopsy market over the forecast period.
Inquire before buy: https://www.marketdataforecast.com/market-reports/global-liquid-biopsy-market-950/request-sample
On the standard of geographical analysis, the worldwide liquid biopsy market is classified into varied regions namely Middle East, North America, Europe, Latin America, and Asia-Pacific, Africa. North America and Europe region are the countries where most of the major activities related to the liquid biopsy are done within the forecast period. However, in the field of cancer analysis, the Asia-Pacific region is responsible for increasing funding for personal public partnerships.
Some of the main firms dominating the liquid biopsy market are HansaBiomed OU, Janssen Diagnostics, Exosome Sciences, Qiagen, Natera, Exosome Diagnostics, Rarecells SAS, Trovagene, Silicon Biosystems, Sysmex Inostics, SRI International, Personal Genome Diagnostics, and Myriad Genetics.
Market Data Forecast is a market research firm offering syndicated research, consults and industry newsletters across various domains & verticals. With a well-established in-house team of experts from diverse fields and outsource research network across 100+ countries, we are the sole research providers for the majority of Fortune 500 companies. Along with the standards of reports being on par excellence, our unique services like free customization, analyst support for the period of six months post to the purchase will be the flag bearers and differentiates us from the rest. Our experience and in-depth understanding of various business environments will be a support to you and your organization in making well-informed decisions.
Name: Mr. Abhishek Shukla
Address: 2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.